Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Chronic Heart Failure Therapy Optimization With CardioRenal Remote Monitoring System (HERMESHF) (HERMESHF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04050904
Recruitment Status : Not yet recruiting
First Posted : August 9, 2019
Last Update Posted : August 9, 2019
Sponsor:
Information provided by (Responsible Party):
CardioRenal

Brief Summary:
This clinical study evaluates short-term feasibility and safety of CardioRenal ExpHeart in patients with worsening heart failure with reduced ejection fraction to optimize pharmacological heart failure treatment.

Condition or disease Intervention/treatment Phase
Heart Failure Device: ExpHeart Not Applicable

Detailed Description:

The study will take place as follows :

The remote monitoring of the biomarkers (5 days a week, between 7am - 12 midday). The home-based monitoring of congestion by Hb and Hte, eGFR using the CKD EPI formula (creatinine) and potassium variables will be measured with point of care devices, after minimally invasive blood sampling operated by the healthcare professional who will manually enter the data in the Information System.

2. ExpHeart is composed of an Information System (web application) and an algorithm, the Expert System, embedded on the information system. The Information System is a cyber-securised web application and the Expert System uses a proprietary therapeutic algorithm to optimize pharmacological HF treatment. The Expert System is based on the analysis of a continuously updated clinical database integrating the patient's electronic medical record (managed by the Information System). The Expert System will generate prescription recommendations directed to the treating investigator through the Information System. The Expert System recommendations are based on ESC clinical guidelines (Annex II). This evaluated solution Expheart is not CE marked yet.

3. Decision on treatment update and/or optimization will be operated by physicians and healthcare professionals who will monitor compliance with the study protocol including the smooth functioning of bilateral patientinvestigator communication, i.e. (i) receipt by the investigator of recommendations from Expheart solution, (ii) adequate action/decision of the investigator and (iii) implementation of the appropriate action at the patient level.

The Investigator will inform the patient's treating physician/General practitioner (by phone and mail) about the participation of his/her patient to the study and will inform him that any HF treatment prescription change will be performed by him/her during the study period.

Moreover, in case of any technical difficulty, assistance will be provided by a dedicated call center, serviced daily by the promotor (Monday to Friday, support@cardio-renal.com).


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Intervention Model: Single Group Assignment
Intervention Model Description: Prospective single-arm open pilot study
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Chronic Heart Failure Therapy Optimization With CardioRenal Remote Monitoring System (HERMESHF)
Estimated Study Start Date : August 15, 2019
Estimated Primary Completion Date : January 31, 2020
Estimated Study Completion Date : March 31, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure

Arm Intervention/treatment
Experimental: ExpHeart
The Information System is a cyber-securised web application and the Expert System uses a proprietary therapeutic algorithm to optimize pharmacological HF treatment.
Device: ExpHeart
ExpHeart is composed of an Information System (web application) and an algorithm, the Expert System, embedded on the Information System. The Information System is a cyber-securised web application and the Expert System uses a proprietary therapeutic algorithm to optimize pharmacological HF treatment. The Expert System is based on the analysis of a continuously updated clinical database integrating the patient's electronic medical record (managed by the Information System). The Expert System will generate prescription recommendations directed to the treating investigator through the Information System.




Primary Outcome Measures :
  1. Hospitalization [ Time Frame: 5 weeks ]
    All cause hospitalization (total number of participants hospitalized for any cause)

  2. Mortality (number of all cause death) [ Time Frame: 5 weeks ]
    All cause death

  3. Heart failure hospitalization (number of patients hospitalized for heart failure) [ Time Frame: 5 weeks ]

    Heart failure hospitalization defined as:

    • Heart failure related visit to an emergency room
    • Heart failure related visit to an ambulatory heart failure care
    • Heart failure related hospital admissions

  4. Hyperkalemia (number of participants with episode of hyperkaliemia) [ Time Frame: 5 weeks ]
    Hyperkalemia >6 mmol/L (confirmed by immediate recheck on site with vein puncture by the study nurse)

  5. Hypokalemia (number of participants with episode of hypokaliemia) [ Time Frame: 5 weeks ]
    Hypokalemia <3.5 mmol/L (confirmed by immediate recheck on site with vein puncture by the study nurse)

  6. Renal function [ Time Frame: 5 weeks ]
    Number of participants with at least one episode of worsening renal function >50 %, >100 %

  7. Feasibility outcome [ Time Frame: 5 weeks ]
    Number of successful procedures during each study steps from puncture and sampling process to implementation of the specific action at the patient level


Other Outcome Measures:
  1. Pharmacotherapy [ Time Frame: 5 weeks ]
    Number of participants with changes from baseline to 5 weeks post enrollment of doses of ACE inhibitors or ARB or ARNI or MRAs and of loop diuretics

  2. Dose titration [ Time Frame: 5 weeks ]
    Frequency of dose titration of ACE inhibitors or ARB or ARNI or MRAs and of loop diuretics

  3. Rate of patients with optimal therapy [ Time Frame: 5 weeks ]
    Rate of patients receiving optimal therapy of ACE inhibitors or ARB or ARNI or MRAs (i.e. receiving doses > 50% of guideline target doses), alive, and not hospitalized for heart failure

  4. Congestion [ Time Frame: 5 weeks ]
    Changes from baseline to 5 weeks post enrollment in congestion score as assessed by lung comet ultrasound

  5. Changes in BNP [ Time Frame: 5 weeks ]
    Changes from baseline to 5 weeks post enrollment in blood levels of BNP (pg/mL)

  6. Hemoglobin [ Time Frame: 5 weeks ]
    Changes from baseline to 5 weeks in blood hemoglobin concentration (g/L)

  7. Hemoglobin [ Time Frame: 5 weeks ]
    Changes from baseline to 5 weeks in hematocrit (%)

  8. Renal function [ Time Frame: 5 weeks ]
    Changes from baseline to 5 weeks in eGFR (ml/min/1.7 m2) (using the CKD EPI formula)

  9. Blood potassium [ Time Frame: 5 weeks ]
    Changes from baseline to 5 weeks in blood potassium (mmol/L)

  10. Patient experience [ Time Frame: 5 weeks ]
    Sociology survey with questionnaire on subjective experience (Optional sub-study) Changes from baseline to 5 weeks in Health-related Quality of life, measured using the Kansas City Cardiomyopathy Questionnaire (KCCQ)

  11. Exploratory pathophysiological outcomes [ Time Frame: 5 weeks ]

    Correlation between changes in Hb and hematocrit with the following parameters:

    • BNP changes from baseline (pg/mL)
    • Lung comet changes (congestion score as assessed by lung comet ultrasound)
    • HF-related visit to an emergency room (number of visits)
    • HF-related visit to an ambulatory HF care unit (number of visits)
    • HF-related hospital admissions (number of days of hospitalizations)
    • HF-related death (number of deaths due to HF)
    • Administration of an intravenous diuretic (dose of intravenous diuretic)
    • Increase in dose of, or addition of a new, oral diuretic



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects who understand the study procedures and agree to participate by providing informed consent.
  • Male or female aged ≥18 years
  • Subjects with worsening HF:

    1. Currently admitted to hospital with worsening heart failure, OR
    2. Discharged within 2 weeks from hospitalization with worsening heart failure AND
    3. HF with reduced ejection fraction (i.e. ejection fraction ≤ 35% documented within 6 months before enrolment)
    4. NT-proBNP > 1000 pg/ml, or BNP > 200 pg/ml. For subjects with atrial fibrillation, BNP must be > 700 pg/ml or NT-proBNP > 2500 pg/ml.
    5. Receiving suboptimal therapy i.e. no doses or doses < 50% of guideline target optimal of ACE inhibitors or ARB or ARNI or MRA (as per ESC guidelines recommendations, Annex II) AND at risk of developing hyperkalaemia or worsening renal function i.e. ANY of the following:

      1. documented history of hyperkalaemia or of worsening renal function leading to ACE-I or ARB or ARNI or MRA down-titration or discontinuation,
      2. age > 75 years,
      3. eGFR < 50 ml/min/1.73 m2 anytime during hospitalization (using the CKD EPI formula),
      4. diabetes.

Exclusion Criteria:

  • Subjects with newly diagnosed heart failure within the past 3 months.
  • Subjects known to be poorly adherent to their HF medications/treatment regimen.
  • Subjects who have had a non-cardiac surgical procedure or cardiac-related interventional procedure (for example but not limited to angiogram, CABG, angioplasty or pacemaker insertion) within the past 30 days.
  • Subjects who have had an ACS, or MI, within the past 30 days.
  • Subjects with eGFR <30 ml/min/1.73m2 (using CKD EPI formula)
  • Subjects with life expectancy less than 3 months in the opinion of the investigator

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04050904


Contacts
Layout table for location contacts
Contact: Ursula Morjaria, MBA 0032477233270 umorjaria@cardio-renal.com

Sponsors and Collaborators
CardioRenal
Investigators
Layout table for investigator information
Principal Investigator: Alexandre Mebazaa, MD Hôpital Lariboisière

Additional Information:
Layout table for additonal information
Responsible Party: CardioRenal
ClinicalTrials.gov Identifier: NCT04050904     History of Changes
Other Study ID Numbers: CR-2018-001
First Posted: August 9, 2019    Key Record Dates
Last Update Posted: August 9, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by CardioRenal:
heart failure
algorithm
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Heart Diseases
Cardiovascular Diseases